Atherogenic refers to anything that promotes atherosclerosis, the process by which fatty, cholesterol-rich deposits called plaques build up inside artery walls and gradually narrow or harden them. The process begins when certain cholesterol-carrying particles get trapped beneath the inner lining of blood vessels, triggering a chain of immune and inflammatory reactions that can silently progress for decades before causing a heart attack or stroke. The risk factors that drive this process span lipid levels, blood pressure, blood sugar, smoking, genetics, and a handful of less familiar contributors that researchers are still working to understand.
How the Process Starts
The earliest event in atherogenesis is deceptively simple: cholesterol-rich particles slip through the thin inner lining of an artery and get stuck in the wall beneath it. These particles all carry a protein called apolipoprotein B (apoB) on their surface, which is essentially their identification badge. Once lodged in the artery wall, they bind to structural molecules there, and that binding is what keeps them trapped rather than drifting back into the bloodstream.1PubMed. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications This retention step is so central that researchers describe it as the initiating event of the entire disease. Without particles getting stuck, the downstream cascade of inflammation and plaque growth does not occur.2PubMed Central. Increased transvascular retention of atherogenic lipoproteins in type 2 diabetes relates to their enhanced proteoglycan binding
From Trapped Particles to Foam Cells
Once trapped beneath the arterial lining, those apoB-containing particles undergo chemical changes, primarily oxidation. Oxidized LDL is like a distress signal: it attracts immune cells, especially white blood cells called macrophages, which arrive to clean up the mess. The problem is that macrophages are not built to handle large amounts of cholesterol. They engulf the oxidized particles aggressively but cannot process them efficiently, so cholesterol accumulates inside the cells until they become bloated, lipid-stuffed “foam cells.”3PubMed Central. Modification macrophage to foam cells in atherosclerosis disease: some factors stimulate or inhibit this process Research has shown that this uptake depends on specific surface receptors on the macrophage, particularly one called CD36, working alongside an enzyme called PLD2. Without that pairing, macrophages cannot fully take in the oxidized particles.4PubMed Central. Oxidized LDL phagocytosis during foam cell formation in atherosclerotic plaques relies on a PLD2-CD36 functional interdependence
Foam cell accumulation forms what pathologists call a “fatty streak,” the earliest visible sign of atherosclerosis. At this stage the process is still potentially reversible. But if the conditions that started it persist, the streak grows, attracts more immune cells, and matures into a full plaque.
The Inflammation Loop That Keeps Plaques Growing
Atherogenesis is not just a plumbing problem of cholesterol clogging arteries. It is fundamentally an inflammatory disease. Once oxidized lipids and cholesterol crystals accumulate inside a developing plaque, they activate a molecular alarm system in macrophages called the NLRP3 inflammasome. This alarm triggers the release of powerful inflammatory signals, particularly interleukin-1β (IL-1β) and interleukin-18, which recruit still more immune cells and amplify the local inflammatory response.5PubMed. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis Cholesterol crystals and oxidized LDL are among the strongest triggers for this inflammasome activation within the plaque.6PubMed Central. Role of NLRP3 Inflammasomes in Atherosclerosis
The result is a self-reinforcing cycle: retained lipoproteins attract immune cells, immune cells generate inflammation, inflammation damages the vessel wall further and makes it more permeable to additional lipoproteins, and so on. This loop also promotes oxidative stress and endothelial dysfunction, both of which accelerate the process.7PubMed Central. Portrayal of NLRP3 Inflammasome in Atherosclerosis: Current Knowledge and Therapeutic Targets
Smooth muscle cells in the artery wall also get pulled into this cycle. They can change their identity under inflammatory signals, losing their normal structural role and taking on characteristics of macrophages. This shape-shifting promotes further inflammation and plaque instability.8PubMed Central. Vascular Smooth Muscle Cells in Atherosclerosis
Why ApoB Particle Count Matters More Than Cholesterol Numbers
Standard blood tests report LDL cholesterol as the primary atherogenic marker, but there is a growing consensus among lipid experts that measuring apoB gives a more accurate picture of your risk. The reason is straightforward: every atherogenic lipoprotein particle carries exactly one apoB molecule. Measuring apoB tells you how many of those particles are circulating, while LDL cholesterol tells you how much cholesterol is packed inside them. Two people can have identical LDL cholesterol levels but very different numbers of particles, and the person with more particles faces higher risk because more particles means more opportunities for retention in artery walls.9PubMed. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel
Multiple expert panels have found that apoB can be measured more accurately and precisely than LDL cholesterol, and that it does a better job of predicting who will develop cardiovascular disease and whether treatment is working.10PubMed Central. Standardization of Apolipoprotein B, LDL-Cholesterol, and Non-HDL-Cholesterol Despite this, most routine lab work still reports LDL cholesterol rather than apoB, which means some people at elevated risk slip through the cracks, particularly those with smaller, denser LDL particles or with high triglycerides, both of which make LDL cholesterol an unreliable stand-in for particle count.
Lipoprotein(a), the Genetic Risk Factor You Cannot Diet Away
Lipoprotein(a), often written as Lp(a), is a type of apoB-containing particle with an extra protein tacked onto it. What makes it distinctive is that your Lp(a) level is almost entirely genetic. Roughly 70 to 90 percent or more of the variation in Lp(a) levels between people is determined by inherited differences in the LPA gene.11PubMed Central. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease Diet, exercise, and most standard cholesterol-lowering medications have little effect on it.
High Lp(a) is now recognized as an independent and causal risk factor for atherosclerotic cardiovascular disease. It promotes atherogenesis through the usual lipoprotein-retention pathway, but it also adds pro-inflammatory and pro-thrombotic effects on top of that, making plaques both more likely to form and more likely to trigger a clot.12PubMed Central. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk The genetic control over Lp(a) is well established: specific variations in the LPA gene, including the number of repeating structural segments called kringle IV repeats, strongly influence circulating levels. More repeats generally mean lower blood levels, and fewer repeats mean higher, riskier concentrations.13PubMed Central. Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
Because Lp(a) resists most lifestyle changes, many people with high levels don’t know they carry this risk. It is not part of a standard lipid panel in most countries, so you typically have to request the test specifically.
Triglyceride-Rich Remnants
LDL gets most of the attention, but it is not the only atherogenic particle. When your body digests dietary fat or the liver exports fat into the bloodstream, it packages triglycerides into large particles. As those particles circulate, enzymes strip away their triglycerides, leaving behind smaller, cholesterol-enriched remnants. These remnants are apoB-containing particles too, and recent research shows they contribute to atherosclerosis independently of LDL cholesterol.14PubMed Central. Triglycerides, Triglyceride-Rich Lipoproteins, and Remnant Cholesterol in Atherosclerotic Cardiovascular Disease People with chronically elevated triglycerides tend to have more of these remnants circulating, and because the remnants are small enough to penetrate the artery wall yet cholesterol-rich enough to be retained there, they can be particularly atherogenic particle for particle.
What Smoking Does to Arteries
Cigarette smoking accelerates atherosclerosis at every stage, from the very first damage to the artery lining all the way through to the clot that causes a heart attack.15PubMed. The pathophysiology of cigarette smoking and cardiovascular disease: an update The core injury starts with the endothelium, the single-cell-thick lining of every blood vessel. Smoke exposure floods the vascular system with reactive oxygen species, which destroy nitric oxide, a molecule the endothelium depends on to keep vessels relaxed and resistant to plaque formation. With nitric oxide depleted, the endothelium becomes dysfunctional: it allows more inflammatory cells to stick and cross into the artery wall, and it shifts toward a state that promotes clotting.16PubMed Central. Tobacco smoking and vascular biology and function: evidence from human studies
Beyond that initial endothelial damage, smoking increases the oxidation of LDL particles, making them more likely to be engulfed by macrophages and form foam cells. It also promotes platelet stickiness and boosts systemic inflammation. These overlapping mechanisms are why smoking is such a potent atherogenic risk factor, compounding lipid-driven damage with direct vascular injury and a heightened tendency to clot.17PubMed. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis
Hypertension and the Mechanical Side of Plaque Formation
High blood pressure does not just stress the heart; it physically damages artery walls. Every heartbeat sends a pulse of pressure through the arterial system, and in people with hypertension, that pulse hits harder and more frequently than the vessel wall is designed for. Research using stress modeling has shown that the mechanical force from elevated pulse pressure reaches its peak in the innermost layers of the artery wall, exactly where plaques tend to develop.18PubMed Central. Stress distribution in the walls of major arteries: implications for atherogenesis This repeated mechanical strain damages the endothelium and the structural fibers beneath it, making the wall more permeable to LDL particles and more susceptible to the retention-inflammation-foam cell cascade described earlier.
Endothelial dysfunction itself is both a consequence and a driver of hypertension. When endothelial cells cannot produce enough nitric oxide, arteries lose their ability to relax properly, which raises blood pressure further. That pressure damages more endothelium, which reduces nitric oxide output even further.19PubMed. Role of endothelial dysfunction in atherosclerosis Treating high blood pressure breaks this cycle and is one of the most effective ways to slow atherogenesis.
Insulin Resistance and Diabetes
People with type 2 diabetes face a substantially higher risk of atherosclerotic disease, and the connection runs deeper than the elevated blood sugar alone. Insulin resistance, the metabolic state where tissues stop responding normally to insulin, often precedes diabetes by years and is itself an independent predictor of plaque progression, even in people whose blood sugar has not yet crossed the diabetic threshold.20PubMed Central. Atherosclerosis and Insulin Resistance: Is There a Link Between Them? Insulin resistance creates a cluster of atherogenic conditions at once: it raises triglycerides, shrinks and densifies LDL particles, promotes chronic low-grade inflammation, and directly impairs endothelial function. Elevated blood sugar itself also accelerates LDL oxidation and increases the stickiness of artery walls to immune cells.
In people with diabetes, the atherogenic lipoproteins may also bind more tightly to the structural molecules in artery walls, increasing their retention and speeding plaque growth.2PubMed Central. Increased transvascular retention of atherogenic lipoproteins in type 2 diabetes relates to their enhanced proteoglycan binding This helps explain why cardiovascular disease is the leading cause of death in people with diabetes, and why aggressive management of lipids and blood pressure matters as much as blood sugar control for these patients.
Dietary Fats and How They Shift Your Lipid Profile
Not all dietary fats carry the same atherogenic potential. Saturated fat raises LDL cholesterol in part by reducing the number of LDL receptors on liver cells. These receptors are responsible for pulling LDL particles out of the bloodstream, so fewer receptors means more LDL circulating longer. A controlled study in healthy adults found that cutting saturated fat intake increased LDL-receptor abundance by about 10 percent and lowered LDL cholesterol by a similar margin.21PubMed. Reducing saturated fat intake is associated with increased levels of LDL receptors on mononuclear cells in healthy men and women
Trans fats, found in partially hydrogenated oils and some processed foods, are widely considered the most atherogenic dietary fat. They raise LDL cholesterol through a related but distinct mechanism: trans fatty acids get incorporated into cell membranes, increasing membrane cholesterol content and reducing the activity of receptors involved in cholesterol regulation. The combined effect of higher cholesterol content and dampened receptor function contributes to elevated LDL levels in the blood.22PubMed Central. Trans fatty acid derived phospholipids show increased membrane cholesterol and reduced receptor activation as compared to their cis analogs Many countries have now banned or severely restricted industrial trans fats, but they still appear in some food supplies.
When “Good Cholesterol” Is Not So Good
HDL cholesterol has long been called the “good” cholesterol because its primary job is to ferry excess cholesterol away from artery walls and back to the liver for disposal. But the story is more complicated than a simple good-versus-bad framing. What matters is not just how much HDL you have but how well it functions. A large population study found that people in the highest quartile of cholesterol efflux capacity, a measure of how effectively HDL removes cholesterol from cells, had about a 67 percent lower risk of cardiovascular events compared to those in the lowest quartile, even after adjusting for HDL cholesterol levels and other standard risk factors.23PubMed Central. HDL cholesterol efflux capacity and incident cardiovascular events
HDL can become dysfunctional. An inflammatory enzyme called myeloperoxidase, which is abundant in atherosclerotic plaques, chemically modifies the main protein on HDL particles. This modification cripples HDL’s ability to remove cholesterol from macrophages and actually turns it into a pro-inflammatory particle, potentially making plaques worse rather than better.24PubMed Central. Dysfunctional HDL and atherosclerotic cardiovascular disease This is one reason why drugs that simply raised HDL cholesterol levels, like certain experimental medications tested in large trials, failed to reduce heart attacks: boosting the number without fixing the function did not help.
What Makes a Plaque Dangerous
Most heart attacks are not caused by the biggest, most flow-restricting plaques. They are caused by vulnerable plaques that rupture. A plaque becomes vulnerable when it has a large lipid-rich core covered by a thin fibrous cap. That cap is what separates the plaque’s inflammatory contents from the bloodstream. When the cap breaks, the contents spill out and trigger an immediate clotting response that can block the artery entirely. Plaque rupture is estimated to cause about three out of every four fatal blood clots in coronary arteries.25PubMed. From vulnerable plaque to atherothrombosis
The rupture itself is a localized event: it happens at a specific thin spot in the cap, not because the whole plaque is inflamed uniformly. Enzymes released by macrophages and foam cells inside the plaque actively digest the cap’s structural fibers, weakening it until it gives way.26PubMed Central. Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management This is why controlling inflammation and lipid levels matters even after a plaque has formed: stabilizing the cap can prevent rupture even if the plaque itself does not shrink.
Familial Hypercholesterolemia and Genetic Predisposition
Some people are dealt a genetic hand that makes atherogenesis nearly inevitable without treatment. Familial hypercholesterolemia (FH) is an inherited condition in which mutations in genes controlling LDL receptor function leave the body unable to clear LDL particles from the blood efficiently. People with FH have very high LDL cholesterol from birth and can develop atherosclerotic cardiovascular disease decades earlier than average. Newer medications called PCSK9 inhibitors have shown strong effectiveness in lowering LDL cholesterol in these patients.10PubMed Central. Standardization of Apolipoprotein B, LDL-Cholesterol, and Non-HDL-Cholesterol FH affects roughly 1 in 250 people, though many remain undiagnosed because elevated cholesterol is often attributed to lifestyle rather than genetics.
Emerging and Less Familiar Risk Factors
Beyond the traditional risk factors, researchers have identified several newer contributors to atherogenesis that are reshaping how the disease is understood.
Clonal Hematopoiesis
As people age, some of their bone marrow stem cells acquire DNA mutations that give them a growth advantage, producing expanding clones of blood cells. This phenomenon, called clonal hematopoiesis of indeterminate potential (CHIP), becomes common after middle age. The mutant immune cells generated by CHIP are more inflammatory than normal cells, and studies in animal models have shown that they accelerate atherosclerosis, thrombosis, and heart failure by ramping up inflammatory responses, including activation of the same NLRP3 inflammasome pathway that cholesterol crystals trigger inside plaques.27PubMed Central. Clonal hematopoiesis in cardiovascular disease and therapeutic implications CHIP may help explain why cardiovascular risk rises so steeply with age even in people who control their traditional risk factors.28PubMed Central. Clonal Hematopoiesis of Indeterminate Potential From a Heart Failure Specialist’s Point of View
The Gut Microbiome and TMAO
Your gut bacteria produce a compound called trimethylamine when they digest certain nutrients found in red meat, eggs, and dairy. The liver then converts trimethylamine into trimethylamine N-oxide, or TMAO. Elevated TMAO levels have been linked to higher cardiovascular risk, and the compound appears to promote atherogenesis through several of the same pathways that other risk factors use: it impairs endothelial function, activates platelets, and promotes clot formation.29PubMed Central. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide The practical implications are still being worked out. Researchers know the association is real, but whether lowering TMAO through dietary changes or microbiome interventions will reduce heart attacks is not yet settled.
Chronic Infections
Certain persistent infections may add to atherogenic risk. Two pathogens in particular, Chlamydia pneumoniae (a common respiratory bacterium) and cytomegalovirus (a widespread virus), can infect blood vessel wall cells and persist there in a latent state. Both organisms can provoke inflammatory and immune responses in the cells of the artery wall and in the immune cells that populate atherosclerotic plaques.14PubMed Central. Triglycerides, Triglyceride-Rich Lipoproteins, and Remnant Cholesterol in Atherosclerotic Cardiovascular Disease The evidence here is suggestive rather than conclusive. Large trials of antibiotics aimed at clearing Chlamydia from atherosclerotic patients did not reduce heart attacks, which tempered initial enthusiasm for the infection hypothesis. Still, the concept of cumulative “pathogen burden,” in which carrying multiple chronic infections amplifies background vascular inflammation, remains an active area of research.
Autoimmune Disease
People with systemic autoimmune conditions like rheumatoid arthritis and lupus face a substantially elevated risk of atherosclerotic cardiovascular disease. The chronic, system-wide inflammation that defines these diseases overlaps heavily with the inflammatory pathways that drive plaque formation: elevated cytokines, endothelial activation, and immune cell infiltration of vessel walls. In these patients, the atherogenic process is turbocharged by years of uncontrolled immune activation, and cardiovascular disease is a major contributor to mortality in both conditions.